ClinicalTrials.gg
CompletedNCT02756364Updated Feb 8, 2023Results posted

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

A Phase 2 interventional study of Fulvestrant and Sapanisertib in Breast Neoplasms, sponsored by Calithera Biosciences, Inc. Completed at 53 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Calithera Biosciences, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The primary purpose of this study is to compare the progression free survival (PFS) of participants treated with the combination of fulvestrant plus daily sapanisertib and fulvestrant plus weekly sapanisertib versus participants treated with single-agent fulvestrant.

Read the detailed description

The drug being tested in this study is called sapanisertib. Sapanisertib is being tested to treat postmenopausal women with advanced or metastatic estrogen receptor (ER) positive, human epidermal growth factor receptor-2 (HER2) negative breast cancer that has progressed during or after aromatase inhibitor (AI) therapy. This study will evaluate the efficacy and safety of combination of fulvestrant + daily sapanisertib and fulvestrant + weekly sapanisertib compared with fulvestrant alone.

The study will enroll approximately 153 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • Fulvestrant 500 mg
  • Fulvestrant 500 mg + Sapanisertib 4 mg
  • Fulvestrant 500 mg + Sapanisertib 30 mg

All participants will receive either fulvestrant 500 mg intramuscularly (IM), fulvestrant 500 mg + sapanisertib 4 mg daily or fulvestrant 500 mg + sapanisertib 30 mg weekly.

This multicenter trial will be conducted Spain and the USA. Participants will make multiple visits to the clinic, and end of treatment (EOT) visit which will occur 30 to 40 days after receiving their last dose of study drug or before the start of any subsequent anticancer therapy. After EOT, participants will be followed for progression free survival (PFS) and overall survival (OS).

02

Conditions studied

  • Breast Neoplasms

Browse trials for

Keywords

  • Drug Therapy
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's enrollment of 141 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Calithera Biosciences, Inc is the lead sponsor of 29 studies on the registry; none are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 10 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female participants aged 18 years or older who are .
  2. proven diagnosis of breast cancer with evidence of disease or locoregional recurrence.
  3. Histological confirmation and documentation of estrogen receptor (ER)-positive status (≥1% positive stained cells).
  4. Histological or cytological confirmation and documentation of human epidermal growth factor receptor-2 ()-negative status by local laboratory testing using criteria in the American Society of Oncology (ASCO)/College of American Pathologists (CAP) Clinical Practice Guideline update.
  5. defined as either of the following:

    • At least 1 extra-osseous lesion that could be accurately measured in at least 1 dimension.
    • The lesion must have measured ≥20 mm with conventional imaging techniques or ≥10 mm with spiral CT or MRI. Lymph nodes must be ≥1.5 cm in the short axis to be considered measurable.
    • Bone lesions (lytic or mixed [lytic plus sclerotic]) in the absence of measurable disease as defined above. Note: Participants with sclerotic/osteoblastic bone lesions only, in the absence of measurable disease, were not eligible.
  6. Progressive Disease (PD) during prior aromatase inhibitor (AI) therapy.
  7. Have a history of provided that all of the following criteria are met:

    • Brain metastases have been treated.
    • No evidence of PD for ≥3 months before the first dose of study drug.
    • No hemorrhage after treatment.
    • Off dexamethasone treatment for ≥4 weeks before the first dose of study drug.
    • No ongoing requirement for dexamethasone or anti-epileptic drugs.
  8. (ECOG) performance status of 0 or 1.
  9. Clinical laboratory values as specified below within 4 weeks before the first dose of study drug:

    • Bone marrow reserve consistent with (ANC) ≥1.5*10\^9/L; count ≥100*10\^9/L; (Hgb) ≥9 g/dL.
    • Total ≤1.5*the (ULN), (AST) and alanine aminotransferase (ALT) ≤2.5*ULN (≤5*ULN if liver metastases are present).
    • ≥40 mL/min based on Cockcroft-Gault estimate or based on a 12- or 24-hour urine collection.
    • Fasting serum glucose ≤130 mg/dL and fasting triglycerides ≤300 mg/dL.

Exclusion criteria

Exclusion Criteria:

  1. Prior therapy with mechanistic target of rapamycin (mTOR), phosphoinositide-3-kinase (PI3K), or dual PI3K-mTOR inhibitors, serine/threonine-specific protein kinase (AKT) inhibitors, or fulvestrant.
  2. Prior treatment with >1 for breast cancer or for locoregional recurrence that was not amenable to resection or radiation therapy with curative intent.
  3. Experienced PD on >2 endocrine therapies for metastatic breast cancer or for locoregional recurrence that was not amenable to resection or radiation therapy with curative intent.
  4. Life-threatening metastatic visceral disease (defined as extensive hepatic involvement or symptomatic pulmonary lymphangitic spread).
  5. Poorly controlled diabetes mellitus defined as (glycosylated ; HbA1c) >7%; participants with a history of transient glucose intolerance due to administration may be eligible if all other inclusion/exclusion criteria are met.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
141 participants (actual)

Study arms

  • Active comparator
    Fulvestrant 500 mg

    Fulvestrant 500 mg, intramuscularly (IM), once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 16.0 weeks).

    Drug: Fulvestrant

  • Experimental
    Fulvestrant 500 mg + Sapanisertib 4 mg

    Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with the sapanisertib 4 mg, capsules, orally, once daily in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 20.1 and 20.3 weeks for fulvestrant and sapanisertib respectively).

    Drug: Fulvestrant · Drug: Sapanisertib

  • Experimental
    Fulvestrant 500 mg + Sapanisertib 30 mg

    Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with sapanisertib 30 mg, capsule, orally, once weekly in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 17.0 weeks for fulvestrant and sapanisertib, each).

    Drug: Fulvestrant · Drug: Sapanisertib

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

    Time frame: Up to 40 months

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death.

    Time frame: Up to 164 weeks

  2. Time to Progression (TTP)

    TTP was defined as the time from the date of randomization to the date of first documentation of progression. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

    Time frame: Up to 40 months

  3. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who achieve a best response of complete response (CR) or partial response (PR) according to RECIST v1.1 criteria. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.

    Time frame: Up to 40 months

  4. Clinical Benefit Rate (CBR)

    CBR was defined as the percentage of participants who achieved a best response of CR, PR, or stable disease (SD) of any duration. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: Up to 40 months

  5. Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: Up to 164 weeks

07

Results

Posted Dec 19, 2020

Participant flow

Participants took part in the study at 50 investigative sites in Spain and the United States from 28 July 2016 to 25 November 2019. After all data was collected and participants were transitioned to post-trial access, the Sponsor stopped the study site, defined as 'Site terminated by the Sponsor'.

Participant flow — Overall Study
MilestoneArm A: Fulvestrant 500 mgArm B: Fulvestrant 500 mg + Sapanisertib 4 mg QDArm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW
Started464748
Treated participants464747
Completed000
Not completed464748
Withdrew: Site terminated by sponsor243021
Withdrew: Death201518
Withdrew: Withdrawal by patient218
Withdrew: Lost to follow-up011

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Time frame:
Up to 40 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsArm A: Fulvestrant 500 mgArm B: Fulvestrant 500 mg + Sapanisertib 4 mg QDArm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW
Progression Free Survival (PFS)3.5 (1.9 to 5.6)7.2 (3.9 to 10.6)5.6 (4.1 to 9.0)
Statistical analysis
  • Arm A: Fulvestrant 500 mg vs Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD · Log Rank · p = 0.537 · Hazard ratio (hr): 0.77 · 95% CI 0.47 to 1.26HR obtained by stratified Cox proportional hazard model with treatment arm, original interactive response technology (IRT) stratification factors as covariates. A hazard ratio of \<1 was considered statistically significant.
  • Arm A: Fulvestrant 500 mg vs Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW · Log Rank · p = 0.849 · Hazard ratio (hr): 0.88 · 95% CI 0.53 to 1.45HR obtained by stratified Cox proportional hazard model with treatment arm, original IRT stratification factors as covariates. A hazard ratio of \<1 was considered statistically significant.
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death.

Time frame:
Up to 164 weeks
Reported as:
Median · months
Overall Survival (OS)
monthsArm A: Fulvestrant 500 mgArm B: Fulvestrant 500 mg + Sapanisertib 4 mg QDArm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW
Overall Survival (OS)30.5 (21.5 to NA)NA (29.9 to NA)34.2 (20.0 to NA)
Statistical analysis
  • Arm A: Fulvestrant 500 mg vs Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD · Log Rank · p = 0.276 · Hazard ratio (hr): 0.71 · 95% CI 0.36 to 1.40HR obtained by stratified Cox proportional hazard model with treatment arm, original IRT stratification factors as covariates. A hazard ratio of \<1 was considered statistically significant.
  • Arm A: Fulvestrant 500 mg vs Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW · Log Rank · p = 0.470 · Hazard ratio (hr): 0.89 · 95% CI 0.47 to 1.68HR obtained by stratified Cox proportional hazard model with treatment arm, original IRT stratification factors as covariates. A hazard ratio of \<1 was considered statistically significant.
SecondaryTime to Progression (TTP)

TTP was defined as the time from the date of randomization to the date of first documentation of progression. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Time frame:
Up to 40 months
Reported as:
Median · months
Time to Progression (TTP)
monthsArm A: Fulvestrant 500 mgArm B: Fulvestrant 500 mg + Sapanisertib 4 mg QDArm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW
Time to Progression (TTP)3.5 (1.9 to 5.6)7.2 (5.5 to 10.6)5.6 (4.1 to 9.0)
Statistical analysis
  • Arm A: Fulvestrant 500 mg vs Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD · Log Rank · p = 0.495 · Hazard ratio (hr): 0.76 · 95% CI 0.46 to 1.25HR obtained by stratified Cox proportional hazard model with treatment arm, original IRT stratification factors as covariates. A hazard ratio of \<1 was considered statistically significant.
  • Arm A: Fulvestrant 500 mg vs Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW · Log Rank · p = 0.646 · Hazard ratio (hr): 0.83 · 95% CI 0.49 to 1.38HR obtained by stratified Cox proportional hazard model with treatment arm, original IRT stratification factors as covariates. A hazard ratio of \<1 was considered statistically significant.
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who achieve a best response of complete response (CR) or partial response (PR) according to RECIST v1.1 criteria. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.

Time frame:
Up to 40 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsArm A: Fulvestrant 500 mgArm B: Fulvestrant 500 mg + Sapanisertib 4 mg QDArm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW
Objective Response Rate (ORR)10.921.312.8
Statistical analysis
  • Arm A: Fulvestrant 500 mg vs Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD · Odds ratio (or): 2.23 · 95% CI 0.68 to 7.29The odds ratio and 95% CIs were obtained using a stratified Cochran-Mantel-Haenszel model with the original IRT stratification factors (visceral metastases, previous sensitivity to hormonal therapy, and previous exposure to CDK4/6 inhibitors).
  • Arm A: Fulvestrant 500 mg vs Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW · Odds ratio (or): 1.22 · 95% CI 0.34 to 4.39The odds ratio and 95% CIs were obtained using a stratified Cochran-Mantel-Haenszel model with the original IRT stratification factors (visceral metastases, previous sensitivity to hormonal therapy, and previous exposure to CDK4/6 inhibitors).
SecondaryClinical Benefit Rate (CBR)

CBR was defined as the percentage of participants who achieved a best response of CR, PR, or stable disease (SD) of any duration. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
Up to 40 months
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR)
percentage of participantsArm A: Fulvestrant 500 mgArm B: Fulvestrant 500 mg + Sapanisertib 4 mg QDArm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW
Clinical Benefit Rate (CBR)60.974.566.0
Statistical analysis
  • Arm A: Fulvestrant 500 mg vs Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD · Odds ratio (or): 2.56 · 95% CI 0.94 to 6.94The odds ratio and 95% CIs were obtained using a stratified Cochran-Mantel-Haenszel model with the original IRT stratification factors (visceral metastases, previous sensitivity to hormonal therapy, and previous exposure to CDK4/6 inhibitors).
  • Arm A: Fulvestrant 500 mg vs Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW · Odds ratio (or): 1.75 · 95% CI 0.69 to 4.44The odds ratio and 95% CIs were obtained using a stratified Cochran-Mantel-Haenszel model with the original IRT stratification factors (visceral metastases, previous sensitivity to hormonal therapy, and previous exposure to CDK4/6 inhibitors).
SecondaryPercentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
Up to 164 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)
percentage of participantsArm A: Fulvestrant 500 mgArm B: Fulvestrant 500 mg + Sapanisertib 4 mg QDArm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW
Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)89.1100.0100.0

Adverse events

Collected over Up to 164 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Fulvestrant 500 mg20/46 (43.5%)8/46 (17.4%)38/46 (82.6%)
Arm B: Fulvestrant 500 mg + Sapanisertib 4 mg QD15/47 (31.9%)13/47 (27.7%)47/47 (100%)
Arm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW18/48 (37.5%)8/47 (17%)47/47 (100%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventArm A: Fulvestrant 500 mgArm B: Fulvestrant 500 mg + Sapanisertib 4 mg QDArm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW
Pleural effusionRespiratory, thoracic and mediastinal disorders2/460/470/47
Respiratory failureRespiratory, thoracic and mediastinal disorders2/460/470/47
PneumonitisRespiratory, thoracic and mediastinal disorders0/462/470/47
Pyelonephritis acuteInfections and infestations0/460/472/47
VomitingGastrointestinal disorders0/462/471/47
DiarrhoeaGastrointestinal disorders0/462/470/47
PyrexiaGeneral disorders0/462/470/47
PneumoniaInfections and infestations1/460/470/47
EncephalopathyNervous system disorders1/460/470/47
HeadacheNervous system disorders1/460/470/47
Most frequent other events
Showing 10 of 60
Most frequent other events
EventArm A: Fulvestrant 500 mgArm B: Fulvestrant 500 mg + Sapanisertib 4 mg QDArm C: Fulvestrant 500 mg + Sapanisertib 30 mg QW
NauseaGastrointestinal disorders9/4623/4741/47
VomitingGastrointestinal disorders4/4614/4733/47
HyperglycaemiaMetabolism and nutrition disorders10/4627/4726/47
DiarrhoeaGastrointestinal disorders1/4624/4713/47
AstheniaGeneral disorders11/4613/4721/47
Decreased appetiteMetabolism and nutrition disorders5/4615/4719/47
FatigueGeneral disorders10/4617/4711/47
StomatitisGastrointestinal disorders3/4616/4715/47
PruritusSkin and subcutaneous tissue disorders0/4615/478/47
RashSkin and subcutaneous tissue disorders0/4614/477/47

Baseline characteristics

Full Analysis Set included all randomized participants.

Age, Continuous
Age, Continuous(years)Arm A: Fulvestrant 500 mgArm B: Fulvestrant 500 mg + Sapanisertib 4 mg QDArm C: Fulvestrant 500 mg + Sapanisertib 30 mg QWTotal
Mean60.3 ± 10.1060.3 ± 10.9257.9 ± 12.0459.5 ± 11.05
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Fulvestrant 500 mgArm B: Fulvestrant 500 mg + Sapanisertib 4 mg QDArm C: Fulvestrant 500 mg + Sapanisertib 30 mg QWTotal
Female464748141
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Fulvestrant 500 mgArm B: Fulvestrant 500 mg + Sapanisertib 4 mg QDArm C: Fulvestrant 500 mg + Sapanisertib 30 mg QWTotal
Hispanic or Latino54716
Not Hispanic or Latino374140118
Unknown or Not Reported4217
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Fulvestrant 500 mgArm B: Fulvestrant 500 mg + Sapanisertib 4 mg QDArm C: Fulvestrant 500 mg + Sapanisertib 30 mg QWTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1012
White444544133
More than one race0000
Unknown or Not Reported1236
Region of Enrollment
Region of Enrollment(Participants)Arm A: Fulvestrant 500 mgArm B: Fulvestrant 500 mg + Sapanisertib 4 mg QDArm C: Fulvestrant 500 mg + Sapanisertib 30 mg QWTotal
Spain23343390
United States23131551
08

Study locations

53 sites
  • Southern Cancer Center, PC
    Mobile, Alabama 36608, United States
  • CBCC Global Research 6501 Truxtun Avenue Bakersfield, CA
    Bakersfield, California 93309, United States
  • St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare
    Fullerton, California 92835, United States
  • UCSD Moores Cancer Center
    La Jolla, California 92037, United States
  • UCLA Hematology/Oncology David Geffen School of Medicine
    Los Angeles, California 90095-7077, United States
  • North County Oncology
    Oceanside, California 92056, United States
  • Torrance Health Association
    Redondo Beach, California 90277, United States
  • PHC-SLO Oncology and Hematology
    San Luis Obispo, California 93401, United States
  • Cancer Center of Santa Barbara With Sansum Clinic
    Santa Barbara, California 93105, United States
  • University of Colorado Cancer Center-Anschutz Cancer Pavilion (ACP)
    Aurora, Colorado 80045, United States
  • St. Mary'S Hospital Regional Cancer Center
    Grand Junction, Colorado 81501, United States
  • Rocky mountain cancer centers LLP
    Lakewood, Colorado 80228, United States
  • Holy Cross Hospital- Bienes Cancer Center
    Fort Lauderdale, Florida 33308, United States
  • Memorial Healthcare System
    Hollywood, Florida 33021, United States
  • Orlando Health Inc.
    Orlando, Florida 33806, United States
  • Ft. Wayne Medical Oncology and Hematology, Inc
    Fort Wayne, Indiana 46804, United States
  • New England Cancer Specialists
    Scarborough, Maine 04074, United States
  • Health Partners Institute Park Nicollet Frauenshuh Cancer Center
    Saint Louis Park, Minnesota 55426, United States
  • Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89074, United States
  • New Jersey Hematology & Oncology Associates
    Brick, New Jersey 8724, United States
  • Northern Westchester Hospital Cancer Treatment & Wellness Center
    Mount Kisco, New York 10549, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Texas Oncology, P.A.
    Austin, Texas 78745, United States
  • Texas Oncology - Presbyterian Hospital
    Dallas, Texas 75231, United States
  • Texas Oncology, P.A.
    Dallas, Texas 75246, United States
  • Texas Oncology- South Second Street
    McAllen, Texas 78503, United States
  • Cancer Care Centers of South Texas
    San Antonio, Texas 78217, United States
  • Texas Oncology,PA. Tyler TX, 75702
    Tyler, Texas 75702, United States
  • Virginia Cancer Specialist PC
    Leesburg, Virginia 20176, United States
  • West Virginia University School of Medicine
    Morgantown, West Virginia 26505, United States
  • Consorci Sanitari de Terrassa
    Terrassa, Barcelona 08827, Spain
  • Onkologikoa
    San Sebastian, Guipuzcoa 20014, Spain
  • Hospital Universitari Son Espases
    Palma de Mallorca, Islas Baleares 07120, Spain
  • Hospital Son Llatzer
    Palma de Mallorca, Islas Baleares 07198, Spain
  • Hospital Universitario Puerta del Hierro
    Majadahonda, Madrid 28220, Spain
  • Clinica Universidad de Navarra
    Pamplona, Navarra 31008, Spain
  • Hospital Universitario Sant Joan de Reus
    Reus, Tarragona 43204, Spain
  • Complejo Hospitalario Universitario A Coruna
    A Coruna, 15006, Spain
  • Centro Oncologico de Galicia
    A Coruna, 15009, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic i Provincial
    Barcelona, 08036, Spain
  • Hospital De la Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital San Pedro de Alcantara
    Caceres, 10003, Spain
  • Hospital Universitari Arnau de Vilanova de Lleida
    Lleida, 25198, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28009, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital General Universitario Morales Messeguer
    Murcia, 30008, Spain
  • Hospital Clinico Universitario Virgen de la Arrixaca
    Murcia, 30120, Spain
  • Hospital Universitario Virgen de la Macarena
    Sevilla, 41009, Spain
  • Fundacion Instituto Valenciano de Oncologia
    Valencia, 46009, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Nov 2019, 39 months.

Results were first posted in Dec 2020, 1 year after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 39 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2016
First posted
Apr 29, 2016
StartActual
Jul 28, 2016
Primary completionActual
Nov 25, 2019
CompletionActual
Nov 25, 2019
Results first posted
Dec 19, 2020
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02756364
Responsible party
Sponsor
First posted
Apr 29, 2016
Start date
Jul 28, 2016
Primary completion
Nov 25, 2019
Completion
Nov 25, 2019
Results posted
Dec 19, 2020
Last update
Feb 8, 2023

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sapanisertib

Start the discussion